List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8030003/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Parental drinking, mental health and education, and extent of offspring's healthcare utilisation for anxiety/depression: A HUNT survey and registry study. Scandinavian Journal of Public Health, 2023, 51, 902-910.	1.2	2
2	Parental risk constellations and future alcohol use disorder (AUD) in offspring: A combined HUNT survey and health registries study Psychology of Addictive Behaviors, 2022, 36, 375-386.	1.4	4
3	Cannabis Use during Pregnancy and Risk of Adverse Birth Outcomes: A Longitudinal Cohort Study. European Addiction Research, 2021, 27, 131-141.	1.3	30
4	Prenatal Methamphetamine Exposure and Adverse Neonatal Outcomes: A Nationwide Cohort Study. European Addiction Research, 2021, 27, 97-106.	1.3	11
5	Association Between Prescribed Hypnotics in Infants and Toddlers and Later ADHD: A Large Cohort Study from Norway. Child Psychiatry and Human Development, 2021, 52, 533-543.	1.1	0
6	Opioid maintenance treatment in the Czech Republic, Norway and Denmark: a study protocol of a comparative registry linkage study. BMJ Open, 2021, 11, e047028.	0.8	6
7	Prenatal exposure to <scp>nonâ€steroidal antiâ€inflammatory</scp> drugs and risk of <scp>attentionâ€deficit</scp> /hyperactivity disorder: A <scp>followâ€up</scp> study in the Norwegian mother, father and child cohort. Pharmacoepidemiology and Drug Safety, 2021, 30, 1380-1390.	0.9	2
8	Attentionâ€deficit/hyperactivity disorder in children following prenatal exposure to antidepressants: results from the Norwegian mother, father and child cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 1917-1927.	1.1	10
9	Association of Timing and Duration of Prenatal Analgesic Opioid Exposure With Attention-Deficit/Hyperactivity Disorder in Children. JAMA Network Open, 2021, 4, e2124324.	2.8	5
10	Incidence of diagnosed pediatric anxiety disorders and use of prescription drugs: a nation-wide registry study. European Child and Adolescent Psychiatry, 2020, 29, 1063-1073.	2.8	11
11	Pre conception use of cannabis and cocaine among men with pregnant partners. NAD Nordic Studies on Alcohol and Drugs, 2020, 37, 43-53.	0.7	3
12	Opioid maintenance treatment of pregnant women in the Scandinavian countries. NAD Nordic Studies on Alcohol and Drugs, 2020, 37, 298-312.	0.7	3
13	In utero opioid exposure and risk of infections in childhood: A multinational Nordic cohort study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1596-1604.	0.9	4
14	Nationwide Study of Neuropsychiatric Comorbidity and Medicines Use in Children With Autism Spectrum Disorder in Norway. Frontiers in Psychiatry, 2020, 11, 596032.	1.3	5
15	Associations of Maternal Use of Benzodiazepines or Benzodiazepine-like Hypnotics During Pregnancy With Immediate Pregnancy Outcomes in Norway. JAMA Network Open, 2020, 3, e205860.	2.8	24
16	Prescription of analgesics to long-term survivors of cancer in early adulthood, adolescence, and childhood in Norway: a national cohort study. Pain, 2020, 161, 1083-1091.	2.0	8
17	In utero exposure to analgesic opioids and language development in 5â€year old children. Pharmacoepidemiology and Drug Safety, 2020, 29, 736-744.	0.9	6
18	Socioeconomic characteristics of women with substance use disorder during pregnancy and neonatal outcomes in their newborns: A national registry study from the Czech Republic. Drug and Alcohol Dependence, 2020, 209, 107933.	1.6	8

#	Article	IF	CITATIONS
19	Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and Norway. Pharmacology Research and Perspectives, 2019, 7, e00501.	1.1	5
20	A complete national cohort study of prescriptions of analgesics and benzodiazepines to cancer survivors in Norway 10 years after diagnosis. Pain, 2019, 160, 852-859.	2.0	16
21	Association of Maternal Use of Benzodiazepines and Z-Hypnotics During Pregnancy With Motor and Communication Skills and Attention-Deficit/Hyperactivity Disorder Symptoms in Preschoolers. JAMA Network Open, 2019, 2, e191435.	2.8	34
22	Hospitalization of children after prenatal exposure to opioid maintenance therapy during pregnancy: a national registry study from the Czech Republic. Addiction, 2019, 114, 1225-1235.	1.7	9
23	Association of Constellations of Parental Risk With Children's Subsequent Anxiety and Depression. JAMA Pediatrics, 2019, 173, 251.	3.3	14
24	Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway. Addiction, 2018, 113, 1286-1294.	1.7	25
25	Increase in diagnosis of depressive disorders contributes to the increase in antidepressant use in adolescents. Acta Psychiatrica Scandinavica, 2018, 137, 413-421.	2.2	20
26	Metabolites of Heroin in Several Different Post-mortem Matrices. Journal of Analytical Toxicology, 2018, 42, 311-320.	1.7	21
27	The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents. European Psychiatry, 2018, 49, 16-22.	0.1	9
28	Effect of Time-Dependent Selective Serotonin Reuptake Inhibitor Antidepressants During Pregnancy on Behavioral, Emotional, and SocialÂDevelopment in Preschool-Aged Children. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 200-208.	0.3	49
29	Can measurements of heroin metabolites in post-mortem matrices other than peripheral blood indicate if death was rapid or delayed?. Forensic Science International, 2018, 290, 121-128.	1.3	16
30	Language competence and communication skills in 3-year-old children after prenatal exposure to analgesic opioids. Pharmacoepidemiology and Drug Safety, 2017, 26, 625-634.	0.9	23
31	Mother-reported and prescription registry data on use of hypnotics for children 0–18 months as a risk factor later development of ADHD. European Psychiatry, 2017, 41, S440-S441.	0.1	Ο
32	Longâ€ŧerm Use of Zâ€Hypnotics and Coâ€medication with Benzodiazepines and Opioids. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 292-298.	1.2	24
33	Hypnotics use in children 0–18Âmonths: moderate agreement between mother-reported survey data and prescription registry data. Journal of Pharmaceutical Policy and Practice, 2017, 10, 28.	1.1	1
34	Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study. PLoS ONE, 2017, 12, e0181042.	1.1	28
35	Benzodiazepine prescription for patients in treatment for drug use disorders: a nationwide cohort study in Denmark, 2000–2010. BMC Psychiatry, 2016, 16, 168.	1.1	15
36	Psychotropic drug use among 0–17 year olds during 2004–2014: a nationwide prescription database study. BMC Psychiatry, 2016, 16, 12.	1.1	45

#	Article	IF	CITATIONS
37	Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). International Journal of Epidemiology, 2016, 45, 382-388.	0.9	644
38	Mental disorder diagnoses among children and adolescents who use antipsychotic drugs. European Neuropsychopharmacology, 2016, 26, 1412-1418.	0.3	21
39	Antidepressant drug use among adolescents during 2004–2013: a populationâ€based register linkage study. Acta Psychiatrica Scandinavica, 2016, 134, 420-429.	2.2	15
40	Prenatal Exposure to Folic Acid and Antidepressants and Language Development. Journal of Clinical Psychopharmacology, 2016, 36, 333-339.	0.7	7
41	Motor development in children prenatally exposed to selective serotonin reuptake inhibitors: a large populationâ€based pregnancy cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1908-1917.	1.1	24
42	A Unique Opportunity to Study Short- and Long-Term Consequences in Children Prenatally Exposed to Illicit Drugs and Opioid Maintenance Treatment Using Czech and Scandinavian Registers. Central European Journal of Public Health, 2016, 24, 248-251.	0.4	18
43	A Cohort Study on Long-Term Adverse Effects of Parental Drinking: Background and Study Design. Substance Abuse: Research and Treatment, 2015, 9s2, SART.S23329.	0.5	9
44	Paediatric Offâ€Label Use of Melatonin – A Register Linkage Study between the Norwegian Prescription Database and Patient Register. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 267-273.	1.2	31
45	Prenatal exposure to anxiolytics and hypnotics and language competence at 3Âyears of age. European Journal of Clinical Pharmacology, 2015, 71, 283-291.	0.8	30
46	Commentary on Raitasalo <i>et al</i> . (2015): The great potential in nationâ€wide registers to study prescription drug use and abuse. Addiction, 2015, 110, 644-645.	1.7	0
47	Reduced Prescribing of Benzodiazepines in Denmark and Norway. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 457-458.	1.2	0
48	Prenatal exposure to antidepressants and language competence at age three: results from a large populationâ€based pregnancy cohort in <scp>N</scp> orway. BJOC: an International Journal of Obstetrics and Gynaecology, 2014, 121, 1621-1631.	1.1	58
49	Pharmacokinetic interactions between ethanol and heroin: A study on post-mortem cases. Forensic Science International, 2014, 242, 127-134.	1.3	15
50	Dispensing of benzodiazepines and benzodiazepine-related drugs to pregnant women: a population-based cohort study. European Journal of Clinical Pharmacology, 2014, 70, 1367-1374.	0.8	22
51	Self-reported data on medicine use in the Norwegian Mother and Child cohort study compared to data from the Norwegian Prescription Database. Norsk Epidemiologi, 2014, 24, .	0.2	15
52	Drug exposure: inclusion of dispensed drugs before pregnancy may lead to underestimation of risk associations. Journal of Clinical Epidemiology, 2013, 66, 964-972.	2.4	39
53	Prescription drug use among pregnant women in opioid Maintenance Treatment. Addiction, 2013, 108, 367-376.	1.7	23
54	Midlife vascular risk factors and their association with dementia deaths: Results from a Norwegian prospective study followed up for 35years. Journal of the Neurological Sciences, 2013, 324, 124-130.	0.3	48

#	Article	IF	CITATIONS
55	Association between prescribing hypnotics for parents and children in Norway. Archives of Disease in Childhood, 2013, 98, 732-736.	1.0	10
56	Hypnotic drug use among 0–17 year olds during 2004–2011: A nationwide prescription database study. Scandinavian Journal of Public Health, 2012, 40, 704-711.	1.2	44
57	To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use?. Pain, 2011, 152, 1555-1561.	2.0	35
58	Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during, and after pregnancy: a population-based cohort study. European Journal of Clinical Pharmacology, 2011, 67, 953-960.	0.8	34
59	The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults—a populationâ€based cohort study. Pharmacoepidemiology and Drug Safety, 2011, 20, 90-98.	0.9	19
60	Nicotine Dependence Predicts Repeated Use of Prescribed Opioids. Prospective Population-based Cohort Study. Annals of Epidemiology, 2010, 20, 890-897.	0.9	45
61	Interactions between morphine and the morphine-glucuronides measured by conditioned place preference and locomotor activity. Pharmacology Biochemistry and Behavior, 2009, 93, 1-9.	1.3	9
62	Different time schedules affect conditioned place preference after morphine and morphine-6-glucuronide administration. Pharmacology Biochemistry and Behavior, 2008, 89, 374-383.	1.3	11
63	Behavioural sensitization in mice induced by morphine-glucuronide metabolites. Pharmacology Biochemistry and Behavior, 2008, 90, 578-585.	1.3	8
64	Morphineâ€3â€glucuronide inhibits morphine induced, but enhances morphineâ€6â€glucuronide induced locomotor activity in mice. Pharmacology Biochemistry and Behavior, 2007, 86, 576-586.	1.3	8
65	Conditioned place preference induced by morphine and morphine-6-glucuronide in miceâ^†. Pharmacology Biochemistry and Behavior, 2006, 85, 292-297.	1.3	24
66	Pharmacokinetic differences of morphine and morphine-glucuronides are reflected in locomotor activity. Pharmacology Biochemistry and Behavior, 2002, 73, 883-892.	1.3	72
67	Morphineâ€6â€glucuronideâ€Induced Locomotor Stimulation in Mice: Role of Opioid Receptors. Basic and Clinical Pharmacology and Toxicology, 1998, 82, 3-10.	0.0	19